Please note that the current cost-share program for sacituzumab govitecan-hziy will change (effective 17 June 2024). The new offering will be the second dose in every cycle will be free of charge until a total of eight (8) cycles has been reached. Once eight (8) cycles are reached, the product will qualify to be free of charge. There are detailed Terms and Conditions that you can review on the G.Access portal prior to placing your request. If you have any questions about this new offering, please contact your Gilead representative or email: au.nz.medinfo@gilead.com
